Agilon Health (NYSE:AGL) Stock Price Down 8% – Should You Sell?

Agilon Health, Inc. (NYSE:AGL) traded down 8% on Thursday. The stock traded as low as $78.88 and last traded at $77.7950. 51,105 shares traded hands during trading, a decline of 85% from the average daily volume of 335,643 shares. The stock had previously closed at $84.56.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Truist Financial set a $112.00 price target on Agilon Health and gave the stock a “hold” rating in a research note on Thursday, August 6th. Citigroup raised Agilon Health from a “sell” rating to a “neutral” rating and raised their price objective for the company from $105.00 to $115.00 in a research report on Monday, August 10th. JPMorgan Chase & Co. boosted their target price on shares of Agilon Health from $31.00 to $85.00 and gave the company an “underweight” rating in a report on Monday, August 24th. Royal Bank Of Canada set a $125.00 target price on shares of Agilon Health in a research report on Tuesday, September 15th. Finally, Barclays set a $111.00 price target on shares of Agilon Health and gave the stock an “equal weight” rating in a research note on Thursday, August 6th. Six analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $102.25.

Agilon Health Stock Performance

The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.08 and a current ratio of 1.08. The stock has a market capitalization of $1.35 billion, a P/E ratio of -5.65 and a beta of 3.02. The business has a 50-day moving average price of $93.75 and a 200 day moving average price of $74.15.

Agilon Health (NYSE:AGL) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $1.04 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.90. Agilon Health had a negative return on equity of 119.38% and a negative net margin of 3.92%.The company had revenue of $1.49 billion during the quarter, compared to analyst estimates of $1.45 billion. As a group, sell-side analysts forecast that Agilon Health, Inc. will post -2.9 EPS for the current fiscal year.

Institutional Trading of Agilon Health

Institutional investors have recently bought and sold shares of the company. State Street Corp purchased a new position in Agilon Health in the second quarter worth about $30,024,000. North Peak Capital Management LLC grew its holdings in shares of Agilon Health by 10.8% during the fourth quarter. North Peak Capital Management LLC now owns 38,139,937 shares of the company’s stock valued at $26,267,000 after buying an additional 3,715,460 shares during the last quarter. Rubicon Founders LLC bought a new stake in shares of Agilon Health during the second quarter valued at approximately $11,290,448. Bank of New York Mellon Corp increased its position in shares of Agilon Health by 9.5% during the second quarter. Bank of New York Mellon Corp now owns 35,336 shares of the company’s stock valued at $3,787,000 after acquiring an additional 3,074 shares in the last quarter. Finally, Tidal Investments LLC purchased a new position in Agilon Health in the 2nd quarter worth approximately $1,405,000.

About Agilon Health

Agilon Health, Inc is a healthcare company that partners with independent primary care physicians to support the transition from fee-for-service medicine to value-based care. The company focuses primarily on patients enrolled in Medicare Advantage plans and works with physician groups to coordinate care, improve outcomes and manage healthcare costs.

Agilon provides physicians with technology, analytics, operational support and clinical resources designed to help them manage the health of defined patient populations.